Rhythm Pharmaceuticals, Inc. (RYTM) investor relations documents from the company's IR site: 4 presentations; latest deck 2025-10-31. Read in-app with summaries. First-party data.
Presentation: Setmelanotide demonstrates significant BMI reduction in patients with acquired hypothalamic obesity, regardless of concomitant GLP-1 receptor agonist use.
| Published | Type | Document |
|---|---|---|
| 2025-10-31 | Presentation | Presentation |
| 2025-10-29 | Presentation | Poster |
| 2025-10-24 | Presentation | Poster |
| 2025-10-15 | Presentation | Poster |
RYTM overview · RYTM earnings · RYTM financials · RYTM KPIs · RYTM documents · RYTM ownership · RYTM peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.